Agios Pharmaceuticals price target lowered to $25 from $40 at Goldman Sachs

Goldman Sachs lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $25 from $40 and keeps a Neutral rating on the shares. Shares fell sharply after Phase 3 RISE UP results showed strong hemoglobin responses but missed on sickle cell pain crises and fatigue, two endpoints viewed as essential for broader uptake, the analyst tells investors in a research note. The mixed data raises regulatory and commercial uncertainty ahead of the thalassemia PDUFA and potential REMS implications, with attention now shifting to launch expectations and the company’s longer-term pipeline and strategy, Goldman says.